Figure 4.

A, Predicted binding site between NR2F1‐AS1 and miRNA‐338‐3p by miRcode; (B,C) Dual‐luciferase reporter gene assay and RNA immunoprecipitation assay confirmed the targeted relationship between NR2F1‐AS1 and miR‐338‐3p; (D) miR‐338‐3p was down‐regulated in thyroid cancer (TC) tissues compared with adjacent normal tissues; (E) miR‐338‐3p was significantly decreased in TC cell lines compared with Nthy‐ori 3‐1; (F,G) miR‐338‐3p mimics increased the expression of miR‐338‐3p, which was otherwise decreased by miR‐338‐3p inhibitor compared with negative control (NC) group. **P < 0.01, compared with NC group; ***P < 0.001, compared with lgG group; ^## P < 0.01, compared with inhibitor group